ClinicalTrials.gg
Active, not recruitingNCT07950683Updated Nov 20, 2026

Intercostobrachial Nerve Preservation Versus Transection During Modified Radical Mastectomy

An interventional study of Intercostobrachial Nerve Preservation During Modified Radical Mastectomy and Intercostobrachial Nerve Transection During Modified Radical Mastectomy in Breast Cancer and Post Mastectomy Pain, sponsored by Allama Iqbal Medical College. Active, not recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Allama Iqbal Medical College · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies in Breast Neoplasms with a site in Pakistan — 8 open to participants now, 15 under way, none of them phase 3. Breast Neoplasms · Pakistan.

Enrollment
39th of 40
34 · median 115
Started
2026
with 7 others
No phase
26 of 53
6 open now
Primary completion
2027-05
later than 11 of 14 live
Registered
53rd of 53
by date

Among the 53 studies in Breast Neoplasms with a site in Pakistan, this one is the 39th largest by enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2026, is one of 26 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 53rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 53 studies in Breast Neoplasms with a site in Pakistan are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,575 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Breast Neoplasms with a site in Pakistan, or all of them as a file.
02

Study summary

Breast cancer surgery can cause pain and altered sensation in the armpit and upper arm. During modified radical mastectomy, a nerve called the intercostobrachial nerve may be preserved or cut while lymph nodes are removed from the armpit. This randomized study will compare postoperative pain and the time required for axillary dissection between these two approaches. Thirty-four female patients aged 18 to 75 years with stage I or II breast cancer who are undergoing modified radical mastectomy will be assigned to two groups of 17 participants each. Pain will be assessed after surgery and during follow-up for three months, and the duration of axillary dissection will be measured during the operation. The study aims to assess whether preservation of the nerve is associated with less postoperative pain without a substantial increase in dissection time.

Read the detailed description

This single-center, two-arm randomized controlled trial will be conducted in Surgical Unit I, Jinnah Hospital, Lahore, Pakistan. Eligible female patients undergoing modified radical mastectomy for stage I or II breast cancer will be recruited by non-probability consecutive sampling. Following written informed consent, 34 participants will be randomly assigned in equal numbers to intercostobrachial nerve preservation (n=17) or intercostobrachial nerve transection (n=17) during axillary lymph node dissection. The method of random sequence generation and allocation concealment is not specified in the synopsis and must be documented separately if required by the registry.

The primary objective is to compare postoperative pain. The study synopsis specifies assessment immediately after surgery and at 1, 2 and 3 months; the accompanying case-report questionnaire identifies postoperative day 3 for early pain assessment and month 3 for persistent pain. Pain intensity is recorded on a 0-to-10 pain scale, with 0 representing no pain and 10 representing the worst pain imaginable. Symptoms such as burning, tingling, numbness, shooting pain, and other sensory disturbances in the intercostobrachial nerve distribution will also be documented. Postoperative neuralgia is defined as pain affecting the inner arm or axilla persisting for at least three months after surgery.

The secondary objective is to compare axillary dissection time. An observer will record the time in minutes from the start to the completion of axillary dissection, using a stopwatch. Total operative duration, measured from first skin incision to final skin closure, will also be recorded. Intraoperative complications and postoperative follow-up information will be captured in a structured questionnaire. The protocol proposes descriptive statistics, independent-samples t-tests for quantitative between-group comparisons, chi-square tests for categorical variables, stratification by age and body mass index, and a significance threshold of p \< 0.05. The final statistical analysis plan should specify how repeated pain measurements will be analyzed.

03

Conditions studied

  • Breast Cancer
  • Post Mastectomy Pain

Keywords

  • Intercostobrachial Nerve Preservation; Intercostobrachial Nerve Transection; Axillary Lymph Node Dissection; Postoperative Pain; Operative Time
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 75 years with breast cancer undergoing modified radical mastectomy.
  • Patients with stage I or stage II breast cancer.
  • Patients who provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Previous axillary radiation or breast surgery.
  • Advanced breast cancer, particularly N2 nodal-stage disease.
  • Pre-existing neurological disorders, including diabetic neuropathy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Intercostobrachial Nerve Preservation

    Seventeen planned participants will undergo modified radical mastectomy with preservation of the intercostobrachial nerve during axillary lymph node dissection.

    Procedure: Intercostobrachial Nerve Preservation During Modified Radical Mastectomy

  • Active comparator
    Intercostobrachial Nerve Transection

    Seventeen planned participants will undergo modified radical mastectomy with transection (non-preservation) of the intercostobrachial nerve during axillary lymph node dissection.

    Procedure: Intercostobrachial Nerve Transection During Modified Radical Mastectomy

Interventions

  • ProcedureIntercostobrachial Nerve Preservation During Modified Radical Mastectomy

    During modified radical mastectomy and axillary lymph node dissection, the intercostobrachial nerve is identified and preserved.

  • ProcedureIntercostobrachial Nerve Transection During Modified Radical Mastectomy

    During modified radical mastectomy and axillary lymph node dissection, the intercostobrachial nerve is transected rather than preserved.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Intensity

    Pain intensity is assessed using a 0-to-10 patient-reported pain rating scale described in the protocol as a Visual Analogue Scale (VAS) or Numeric Rating Scale (NRS). The study questionnaire uses whole-number ratings from 0 (no pain) to 10 (worst pain imaginable); higher scores indicate greater pain. Pain in the axillary and upper-arm region is assessed at follow-up visits.

    Time frame: Postoperative day 3 and months 1, 2 and 3 after surgery

Secondary outcomes

  1. Duration of Axillary Lymph Node Dissection

    Time taken for axillary lymph node dissection, recorded in minutes by a designated observer using a stopwatch. Longer times indicate greater dissection duration.

    Time frame: Intra-operatively, from initiation to completion of axillary dissection

  2. Total Operative Time

    Total duration of modified radical mastectomy, recorded in minutes from first skin incision until completion of final skin closure.

    Time frame: Intra-operatively, from initial skin incision to final skin closure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for May 2027, 5 months after the start.

Of 2,669 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 5 months is below that.

Counting every sponsor, half of 2,779 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartActual
Nov 3, 2026
Primary completionEst.
May 2, 2027
CompletionEst.
May 30, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950683
Lead sponsor
Allama Iqbal Medical College
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Nov 3, 2026
Primary completion
May 2, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Dr. Sajjad Hussain, MBBS, FCPS PGR
principal investigator · Surgical Unit I, Jinnah Hospital / Allama Iqbal Medical College, Lahore, Pakistan
Prof. Dr. Farooq Ahmad, MBBS, FCPS
study director · Surgical Unit I, Jinnah Hospital / Allama Iqbal Medical College, Lahore, Pakistan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion